Cosmo Pharma stock drops 16% after €175m CB surprises funds
Shares in Cosmo Pharmaceuticals, the Swiss-listed maker of gastro-intestinal drugs, plummeted by 16% on Thursday after it had launched a €175m convertible bond on Wednesday evening, after market close.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts